Jack Geltosky, Ph.D.
Jack Geltosky has over 27 years of experience in the pharmaceutical field, evenly split between R&D and licensing.
Prior to his 9 year tenure with Skysong Innovations, Geltosky was Vice President of External Science, Technology and Licensing at Bristol Myers Squibb. There he was responsible for the acquisition and licensing of compounds, R&D technologies and intellectual property to support the company’s drug discovery and development efforts. In addition, he was responsible for monitoring the industry to identify, evaluate, and coordinate due diligence on potential in-and out-licensing candidates in pre-clinical and clinical development. Geltosky’s team consisted of 15 licensing professionals.
Prior to joining BMS, Geltosky was President and Chief Executive Officer of Message Pharmaceuticals, a privately-held biotechnology company focused on the discovery of drugs active on RNA. Previously he worked for SmithKline Beecham as Vice President, Scientific Licensing. He also held several other research and development roles of increasing responsibility with Johnson & Johnson, including Senior Director of Research for the Robert Wood Johnson Pharmaceutical Research Institute. Geltosky began his career as a research scientist at E.I. DuPont.
Geltosky holds a B.S. in chemistry from Memphis State University and a Ph.D. in biochemistry from the California Institute of Technology. He sits on the Board of Directors for Enzon Pharmaceuticals, Inc.